New genetic treatments for rare diseases
Official title: Development of novel genetic medicine approaches to treat orphan diseases
Funded at Kinea Bio, INC. · NIH-11328150 · Data updated 2026-11-12
This study is exploring a new way to use special viruses to deliver larger genes that can help treat rare muscle disorders, like dysferlinopathies, by combining two of these viruses to improve treatment outcomes for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kinea Bio, INC. NIH-funded |
| Lab location | 1 site (Mukilteo, UNITED STATES) |
| Project start | September 19, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $55,000 |
| NIH project number | 3R44AR083801-02S1 |
| Project ID | NIH-11328150 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with dysferlinopathies or other muscular dystrophies that require large gene therapies.
✕Less likely to help
Patients with non-genetic muscular disorders or those whose conditions do not involve the dysferlin gene may not benefit from this research.
What this research studies
This research focuses on developing innovative genetic medicine approaches using adeno-associated viral (AAV) vectors to treat rare genetic disorders, particularly those affecting muscles. The team aims to overcome the limitations of AAV vectors, which can only carry small genetic sequences, by using a dual vector strategy to deliver larger genes necessary for effective treatment. By combining two AAV vectors, they hope to enable the expression of full-length proteins that can provide better therapeutic outcomes for patients with conditions like dysferlinopathies. The research will involve testing this approach in animal models to evaluate its effectiveness before considering clinical applications.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from rare muscular diseases caused by genetic mutations.
How similar studies have gone: While the use of AAV vectors has shown promise in other genetic therapies, this specific dual vector approach is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Kinea Bio, INC.
Mukilteo, United States Active
Researchers
- Principal investigator: Childers, Martin K — Kinea Bio, INC.
- Study coordinator: Childers, Martin K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.